Charles Schwab’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-60,500
| Closed | -$224K | – | 3083 |
|
|
2017
Q4 | $224K | Hold |
60,500
| – | – | ﹤0.01% | 2961 |
|
|
2017
Q3 | $248K | Hold |
60,500
| – | – | ﹤0.01% | 2944 |
|
|
2017
Q2 | $225K | Buy |
+60,500
| New | +$240K | ﹤0.01% | 2991 |
|
|
2016
Q4 | – | Sell |
-4,283
| Closed | -$43K | – | 3078 |
|
|
2016
Q3 | $43K | Hold |
4,283
| – | – | ﹤0.01% | 3027 |
|
|
2016
Q2 | $25K | Sell |
4,283
-25,285
| -86% | -$172K | ﹤0.01% | 3091 |
|
|
2016
Q1 | $226K | Hold |
29,568
| – | – | ﹤0.01% | 2862 |
|
|
2015
Q4 | $394K | Hold |
29,568
| – | – | ﹤0.01% | 2750 |
|
|
2015
Q3 | $487K | Hold |
29,568
| – | – | ﹤0.01% | 2635 |
|
|
2015
Q2 | $664K | Buy |
29,568
+7,985
| +37% | +$126K | ﹤0.01% | 2570 |
|
|
2015
Q1 | $212K | Hold |
21,583
| – | – | ﹤0.01% | 2936 |
|
|
2014
Q4 | $247K | Hold |
21,583
| – | – | ﹤0.01% | 2920 |
|
|
2014
Q3 | $249K | Hold |
21,583
| – | – | ﹤0.01% | 2875 |
|
|
2014
Q2 | $420K | Buy |
21,583
+17,300
| +404% | +$305K | ﹤0.01% | 2706 |
|
|
2014
Q1 | $77K | Hold |
4,283
| – | – | ﹤0.01% | 3049 |
|
|
2013
Q4 | $46K | Hold |
4,283
| – | – | ﹤0.01% | 3072 |
|
|
2013
Q3 | $53K | Hold |
4,283
| – | – | ﹤0.01% | 3050 |
|
|
2013
Q2 | $42K | Buy |
+4,283
| New | +$55K | ﹤0.01% | 3036 |
|
Charles Schwab's CASC Position: Q1 2018 in Review
Charles Schwab sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 60,500 shares — an estimated $224K sold.
Charles Schwab first reported a position in CASC in Q2 2013 and held it in 17 quarters. The position peaked at $664K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Charles Schwab reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Charles Schwab sold 60,500 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $224K.
- Charles Schwab first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 17 quarters.
- Charles Schwab's Cascadian Therapeutics, Inc. position peaked at $664K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Charles Schwab's 13F filing for Q1 2018, filed 7 May 2018.